COLUMBUS, OH., 4 March, 2011– Battelle experts will debut a new industry-leading, multi-scale toxicology program as a way to more effectively advance drug development during a Battelle symposium on March 7-10 at the 2011 Society of Toxicology Annual Meeting & ToxExpo in Washington, DC.
“In spite of major investments in pharma and biotech, new drug approvals have decreased or at best stagnated, primarily due to safety concerns,” said Dr. Herb Bresler, Battelle senior research leader. “Battelle’s Multi-Scale Toxicology Initiative (MSTI) helps alleviate these concerns through the advancement of science to help our clients create safer, more effective drugs and biologics.”
Battelle has the unique ability to apply expertise in imaging, systems biology and in vitro assays to enable clients to address today’s most challenging human health issues. Battelle’s comprehensive imaging services and other solutions enable the efforts of MSTI’s streamlining of complex processes for clients by supporting the development of pharmaceutical agents and devices. The application of Battelle’s expertise to develop the next-generation of safety science and toxicology tools reflects Battelle’s significant and constant reinvestment of time and resources to advance science and technology.
MSTI’s goal is to advance the science that underlies the practice of toxicology to result in earlier identification and resolution of safety issues with new drug candidates. Battelle can help biopharmaceutical companies expand their product pipelines and get new drugs and biologics to the market faster.
Battelle’s scientists and researchers pay particular attention to understanding interactions at multiple levels – from molecule to whole organism – and integrating the data from all those levels to generate a system-level view.
A world class team is developing the multi-scale approach. The team includes Battelle, a leader for decades in safety pharmacology; Brookhaven National Laboratory, a pioneer in the development of Positron Emission Tomography (PET) imaging equipment and agents; Lawrence Livermore National Laboratory, a leader in micro and nanodosing techniques using Accelerator Mass Spectrometry; Oak Ridge National Laboratory, which possesses extraordinary materials synthesis capabilities and Pacific Northwest National Laboratory, which has done exceptional work in dosimetry and in-vitro assay.
“Throughout its history, Battelle has built and managed large programs at the forefront of science and technology,” Bresler said. “We have built a wonderful interdisciplinary team that is focused on the most important problems facing safety science and toxicology.”
Experts will be on-hand at the ToxExpo to provide an update on MSTI’s progress and to discuss imaging and other key capabilities being driven by Battelle. Conference attendees can stop by Booth 257 for an update.
As the world’s largest independent research and development organization, Battelle provides innovative solutions to the world’s most pressing needs through its four global businesses: Laboratory Management; National Security; Health and Life Sciences; and Energy, Environment and Material Sciences. It advances scientific discovery and application by conducting $6.2 billion in global R&D annually through contract research, laboratory management and technology commercialization.
Headquartered in Columbus, Ohio, Battelle oversees 22,000 employees in more than 130 locations worldwide, including eight national laboratories for which Battelle has a significant management role on behalf of the U.S. Department of Energy, the U.S. Department of Homeland Security, and the United Kingdom.
Battelle also is one of the nation’s leading charitable trusts focusing on societal and economic impact and actively supporting and promoting science, technology, engineering and mathematics (STEM) education.
For more information contact Katy Delaney at (614) 424-7208 or firstname.lastname@example.org, or T.R. Massey at (614) 424-5544 or email@example.com.